{"schema_version":"secwatch.filing_event.v1","accession":"0001585364-26-000040","form_type":"8-K","ticker":"PRGO","cik":"0001585364","company_name":"PERRIGO Co plc","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.523278+00:00","generated_at":"2026-05-15T00:53:39.639731+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M","bullets":["Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.","Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.","Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.","Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001585364-26-000040","json":"https://secwatch.observer/filing/0001585364-26-000040.json","markdown":"https://secwatch.observer/filing/0001585364-26-000040.md","text":"https://secwatch.observer/filing/0001585364-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/0001585364-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/prgo-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:53:39.639731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"864983cb19241bfd8a31f65fa1c28fa0da4cd0c1","claim":"PERRIGO Co plc completed a disposition involving Karo Healthcare AB for €305.6 million in upfront cash plus up to €27.0 million contingent consideration (closed 2026-04-30).","evidence_excerpt":"On April 30, 2026, the Transaction closed pursuant to the terms of the Agreement. In connection with the closing of the Transaction, Karo made a cash payment to the Company of €305.6 million, including €5.6 million in net working capital adjustments. In addition, the Company may be entitled to additional contingent cash consideration of up to €27.0 million upon","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/0001585364-26-000040-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Karo Healthcare AB"},{"label":"Consideration","value":"€305.6 million in upfront cash plus up to €27.0 million contingent consideration"},{"label":"Closing","value":"2026-04-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}